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Abstract: 
 
Anticancer drugs are prescribed and administrated to an increasing number of patients on a daily 
basis. As a consequence, a number of concerns have been raised about the patient health and safety 
in the case that the drugs administered are not at the required concentration or even worse not the 
correct ones. Quality control of therapeutic solutions has therefore been extensively implemented 
in hospital environments, in order to avoid any failure in the intense workflow faced by 
administering pharmacists. In the present study, infrared (IR) and Raman spectroscopy have been 
employed for the analysis of 3 commercially available therapeutic solutions TEVA®, MYLAN®, 
CERUBIDINE®, respectively containing doxorubicin, epirubicin and daunorubicin. They 
perfectly illustrate the analytical difficulties encountered, as these 3 chemotherapeutic drugs are 
isomers, hardly distinguishable with conventional approaches such as UV/VIS spectrometry. Any 
analytical failure to identify these molecules can lead to delays in patient treatment. While Partial 
Least Squares Regression analysis demonstrates that both Raman and IR can deliver satisfactory 
quantitative analysis in the clinical range, with respective Root Mean Square Error of Cross 
Validation (RMSECV) between 0.0127 – 0.0220 g.L-1 and 0.0573 – 0.0759 g.L-1, the identification 
rate between the 2 techniques differs substantially. Indeed, Principal Component Analysis – 
Factorial Discriminant Analysis (PCA-FDA) highlights that, depending on the data preprocessing 
applied to Raman spectra, the discrimination between the 3 drugs is decreased, with in some cases 
specificity and sensitivity below 50%. However, IR analysis displays encouraging results with an 
overall specificity and sensitivity between 99-100%, suggesting that reliable validation of the 
therapeutic solution for administration to patients can be achieved. IR and Raman spectroscopy 
could assist and support quality control of chemotherapeutic solutions prepared in personalised 
concentrations for each patient. The effective and reliable characterisation of therapeutic solutions 
could have a lot to offer to improve current practices in a near future.  
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I. Introduction: 
Evolutions of clinical procedures and protocols in recent years are motivated by improvement of 
patient safety. Anticancer drugs are extensively used on a daily basis, the number of patients 
treated still increasing annually. Errors in medications are the main risk leading to therapeutic 
failure, which, considering the hazardous nature of most anti-cancers drugs, can have disastrous 
repercussion for a patient’s health. As a result, numerous hospitals have implemented internal 
regulations to standardise their own procedures and minimise the risk of erroneous treatment of a 
patient. High performance liquid chromatography (HPLC) remains the gold standard for 
quantitative analysis of organic compounds as part of daily quality control and is therefore one of 
most commonly found methods in clinical analytical laboratories attached to preparation facilities. 
Mass spectrometry is also a powerful technique for drug screening and analysis, extensively 
employed in the development of new pharmaceutical compounds or patient monitoring through 
detection and quantification in body fluids such as serum, urine or saliva [1, 2]. However, it is not 
currently an option for therapeutic screening applications, due to time constraints of the clinical 
workflow, requirements for sample preparation, and simply the cost involved. However, some 
limitations such as high operating costs, relatively low output and the requirement of specialised 
skills make it less than ideal for routine analysis of chemotherapy preparations [3, 4]. Flow-
injection analysis (FIA) spectroscopic based methods are the most commonly implemented, with 
Ultraviolet-coupled to Fourier-transform infrared spectrometry (UV/vis-FTIR) probably the most 
widespread [5, 6]. Recent evolutions have seen the infrared detection replaced by Raman 
technologies to overcome some of the limitations, but implementation in clinics still requires an 
aliquot to be taken for injection into the analytical device [7, 8]. Moreover, investigations are 
ongoing about the possibility to use Raman spectroscopy as a non-invasive tool to overcome some 
current limitation such as large volume required for FIA, but mostly to avoid any risk in relation 
to exposure of staff to hazardous solutions [9].  
Vibrational spectroscopic techniques, both infrared (IR) absorption and Raman scattering, deliver 
specific molecular fingerprinting signatures of samples. They have been extensively studied for 
biomedical applications [10, 11] can be used and exploited as novel and accurate methods for 
histopathology [12], cytology [13], biopsy characterisation [14], surgical guidance [15], treatment 
monitoring [16] and drug studies [17]. The rapid, cost effective, label free and non-destructive 
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advantages are indeed often pointed out to highlight the benefits of those techniques, but it is the 
analytical capabilities in terms of both qualitative and quantitative performances are also most 
relevant for a wide range of clinically oriented applications [18, 19]. IR and Raman spectroscopy 
are powerful analytical tools widely used for characterisation of organic molecules such as, for 
example, therapeutic drugs [20]. Although primarily used in industry and research laboratories as 
screening tools to monitor whether a synthesis process has been successful [21], coupling the 
molecular specificity of the spectra collected with optimised quantitative approaches strongly 
promotes the techniques for therapeutic solution screening in the clinical environment [22]. In 
previous studies, although encouraging results are documented for monitoring a number of 
molecules such as ganciclovir [23] or 5FU [24], directly in the infusion bag, the material used for 
the packaging, often polystyrene like, also has strong contributions to the spectra that can limit the 
usable analytical range and lead to difficulties in quantifying and/or identifying the 
chemotherapeutic drugs accurately [25]. Therefore, such developments remain only at the research 
level and no translation into the clinic has been achieved as yet, suggesting that the present 
workflow, entailing analysis of aliquots from the therapeutic solutions is still the most realistic 
approach.  
In the present study, three commercial formulations, TEVA® (Doxorubicin), MYLAN® 
(epirubicin) and CERUBIDINE® (daunorubicin) have been used to evaluate the potential of Raman 
and infrared spectroscopy for the analysis of therapeutic solutions in such a workflow. The 
chemotherapeutic agents are chemically similar, and thus present difficulties in terms of their 
identification and/or quantification with UV absorbance spectroscopy. Consequently, a 
comparative study has been conducted as a demonstration of the potential of vibrational 
spectroscopy as quality control tools for clinical use. A two-step approach to this demonstration 
has been implemented, firstly evaluating the discriminative capabilities of both techniques, 
irrespective of concentrations, by means of Principal Component Analysis (PCA) coupled to 
Factorial Discriminant Analysis (PCA-FDA); and secondly determination of the precision of the 
quantitative analysis of the approaches using the Partial Least Squares Analysis (PLSR).  
 
  
2. Materials and Methods: 
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2.1 Anticancer drugs selected and sample preparation: 
The study includes three commercial anthracycline forms, TEVA® (doxorubicin, injectable 
solution, 2 g.L-1), MYLAN® (epirubicin injectable solution, 2 g.L-1) and CERUBIDINE® 
(daunorubicin, lyophilised powder, 20 mg) which were provided through a collaboration 
established with the University Hospital of Tours. While TEVA® and MYLAN® contain small 
amounts of HCl and NaOH (<1%), CERUBIDINE® has mannitol added to the formulation, in 
concentrations as high as 100 mg per 20 mg daunorubicin. Mannitol is a commonly found excipient 
in commercialized daunorubicin-based chemotherapeutics approved for clinical use. The UCBO 
unit (Unité de Biopharmacie Clinique Oncologique, Tours, France) deals with the preparation of 
anticancer drug formulations directly on site for rapid administration to patients. Based on recent 
clinical protocols, a set of 8 aqueous solutions, with drug concentrations of 2 g.L-1, 1.5 g.L-1, 1 g.L-
1, 0.5 g.L-1, 0.25 g.L-1, 0.125 g.L-1, 0.0625 g.L-1 to 0.03125 g.L-1, corresponding to clinically 
relevant concentrations, have been prepared for each chemotherapeutic drug. The samples were 
prepared from the stock solution using serial dilutions, which were analysed directly with Raman 
and infrared spectroscopy. The procedure has been repeated 5 times in order to obtain 5 
independent sets of spectra. All quoted concentrations refer to the amount of drug present in the 
solution without taking into account excipients. All samples were prepared freshly on the day of 
analysis and stored at 4°C in a dark room to avoid photo-damage prior to spectral analysis. ATR-
IR spectra have also been recorded for mannitol 10 g.L-1 and 0.15625 g.L-1 which correspond to 
the concentrations of mannitol found in CERUBIDINE® 2 g.L-1 and 0.03125 g.L-1, respectively. 
 
1.2 Data collection 
 
The current work flow in place at the UCBO unit (Unité de Biopharmacie Clinique Oncologique, 
Tours, France) is based on a Multipsec® analyser (MICRODOM, France). The pharmacists 
receive between 100 and 150 anticancer drug solutions on a daily basis which require analysis and 
clearance before they are administered to patients. For each individual sample, 1.5 mL is extracted 
to an aliquot and injected in the analyser with a syringe. The protocols employed in this study for 
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Raman and Infrared analysis have been derived from the current procedures and designed to 
improve on the analytical performance.   
 
 
 
1.2.1 Raman spectroscopy analysis 
Raman spectra were collected using a Labram spectrometer (Horiba Jobin-Yvon, France) equipped 
with a 690 nm laser source delivering ~10 mW at the sample. 500 µL of the solution were placed 
in a quartz cuvette and the data was collected by illumining the sample through the wall of the 
cuvette. In order to ensure maximum reproducibility between measurements, a macro sampling 
holder, consisting of a cuvette holder attached to the turret of the microscope was employed. 
Basically, the laser coming out of the turret is reflected by a 45° mirror and directed through the 
quartz cuvette. Although the set up requires larger volumes to perform the analysis, the laser is not 
tightly focused and thus the risk of any photothermal damage is minimised. The spectral range was 
set between 150- 3700 cm-1, resulting in a spectral resolution of about 2.5 cm-1, achieved using a 
300 lines/mm grating. Two accumulations of 20 seconds were taken for each spectrum. 5 
independent sets of dilutions have been prepared for each formulation and analyzed on different 
days to capture possible instrumental variability in measurements. Additionally, 5   spectra have 
been measured for each concentration tested. In total, 200 spectra were recorded over the range of 
concentrations for each anticancer drug included in this study. 
 
 
1.2.2 Infrared spectroscopy analysis 
 
Infrared spectra were recorded with a Frontier spectrometer (Perkin Elmer, France) equipped with 
a multi-reflection (n = 10) Attenuated Total Reflectance (ATR) accessory (Eurolabo, France). The 
IR spectra collected result from 16 scans performed over the range 600 – 4000 cm-1 with a spectral 
resolution of 4 cm-1. A background was acquired (64 scans) and ratioed with the sample spectra 
by the software. 2 μl drops were deposited directly on the diamond crystal and allowed to air dry 
prior to analysis. 5 independent replicates have been measured for each concentration tested, 5 
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spectra recorded each time. In total, 200 spectra were recorded over the range of concentrations 
for each anticancer drug included in this study. The time required to record spectra from one drop 
is about 5 mins, including drying time and data collection, which is comparable to protocols 
currently employed at the Hospital of Tours.   
 
  2.2.3 Data handling: 
The Raman and IR data sets have been pre-processed and analysed using MATLAB (Mathworks, 
USA). For the purpose of the study, although the preprocessing and data analysis steps have been 
broken down as individual procedures subsequently applied to data, one should keep in mind that 
the optimised data processing and analysis protocols are easily incorporated in instrumental 
software and implemented as automated functions. Once the protocol has been established, total 
computational time to apply quantitative and discriminative analysis is less than 1 minute 
a) Discriminative analysis: Raman spectra have been cut in order to focus on the fingerprint 
region (300-1800 cm-1) in which the most relevant spectral features are observed. Pre-processing 
of Raman spectra included baseline correction, using Lieber or Extended Multiplicative Scattering 
Correction (EMSC), followed by vector normalisation. While the Lieber algorithm estimates the 
background by a polynomial function and by an iterative method based on least squares [26], the 
EMSC is more advanced approach allowing to correct for additive baseline effects, multiplicative 
scaling effects, and interference effects [27]. For instance, spectra of deionised water were 
provided to neutralise its contribution to the Raman spectra collected from the different solutions. 
For consistency, infrared spectra have also been reduced to the fingerprint region (600-1800 cm-1) 
prior to being subjected to baseline correction (rubber band) and a vector normalisation. The lower 
limit of the spectral range for ATR-IR is defined by the crystal material, generating a cut-off of 
the signal collected. Compared to Raman spectroscopy, ATR-IR therefore has a reduced range in 
the finger print region, which is inherent to the technique. Once pre-processing was completed, 
both Raman and IR spectra were analysed by PCA [28] and PCA-FDA (PCA-Factorial-
Discrimination-Analysis) [29]. Although PCA is a well-established method for rapid evaluation of 
the data, highlighting the spectral variability present in data sets, more advanced approaches such 
as PCA-FDA are required to deliver information about the discriminative performance of the 
techniques. PCA-FDA includes a 100 fold cross validation through a leave K-out cross validation 
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routine. This approach ensures no replicate of a given sample can be found in both the calibration 
and validation sets and avoids over optimistic outcome of the quantitative analysis [30]. 1/3 of the 
data is selected as a test set, while the 2/3 of the remaining samples were used as calibration and 
validation sets. The test set is kept constant and at each iteration, different combinations of 
randomly selected calibration/validations sets are tested. Ultimately, the results are presented in 
the form of confusion matrices, allowing calculation of the specificity and sensitivity of the 
discrimination analysis performed. 
b) Quantitative analysis: Normalisation procedures should be avoided to preserve the 
intensity to concentration relationship in the data. Therefore, only an offset correction has been 
applied for the spectra pre-processing. PLSR remains the most relevant analysis to evaluate the 
possibility of performing quantitative analysis of systematically varying vibrational spectra [31, 
32]. It is a supervised multivariate technique that is highly specific for quantitative methods, and 
is usually performed via two steps: calibration and validation. Therefore, similarly to the PCA-
FDA a 100 fold leave K-out cross validation was implemented. The output of PLSR provides 
performance criteria defined under the linearity (R2) and precision, also called Root Mean Square 
Error for Cross Validation (RMSECV). Additionally, the lower Limit Of Detection – lower LOD) 
has been estimated based on the work published by Allegrini and al  
 
3. Results and Discussion 
3.1 UV characterisation of anthracycline formulation 
Anthracyclines are a group of cytotoxic compounds used as treatment of a wide variety of cancers, 
from leukemia, thyroid, lung and other neoplasia, ovarian, breast, lung and gastric cancer [33] 
leading to a large number of solutions being prepared on a daily basis for patients under 
chemotherapeutic treatment. Doxorubicin, epirubicin and daunorubicn are composed of 
tetracycline aromatic moiety attached to a sugar moiety of daunsamine via a glyosidic bond. As 
displayed in Figure 1, these 3 anthracyclines have the same aromatic chromophore and the 
difference between them concerns the side chains. Notably, epirubicin is a stereoisomer of 
doxorubicin, and differs from it only in the orientation of the hydroxyl group of the hexapyranosyl 
sugar [33]. Daunorubicin differs from doxorubicin only in the shorter side chain terminated with 
a methyl group instead of a primary alcohol group. As a direct consequence, those molecules 
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cannot be discriminated using UV spectrophotometry. The absorbance spectra were collected for 
the 3 molecules in their commercial forms (doxorubicin from TEVA®, epirubicin from MYLAN® 
and daunorubicin from CERUBIDINE®. These spectra have the same profile, with the two main 
maxima located at ca. 480 and 500 nm. NaOH, HCl and mannitol (a sugar) present in the 
commercial forms do not have direct contribution to the UV/Vis spectra in this range, and thus the 
absorbance is solely derived from the drugs. While quantitative analysis is expected to be 
achievable with UV absorbance spectroscopy, difficulties to perform specific identification of the 
chemotherapeutic drugs are understandable. As they contain information of all the moieties of the 
molecule, rather than just the chromophoric π-conjugated structures, vibrational spectra are richer 
in specific molecular structural information than UV-vis absorption spectra. This study aims to 
demonstrate this and optimise protocols to implement the analysis in a clinical workflow. 
              
 
Figure 1: Chemical structures of the 3 anticancer drugs of interest. 
 
3.2. Quantitative and discriminant analysis using Raman spectroscopy  
          3.2.1. Raman characterisation of anthracycline formulations                                     
EpirubicinDoxorubicin Daunorubicin
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Figure 2: Mean macro-Raman spectra recorded from TEVA® (a), MYLAN® (b) and 
CERUBIDINE® (c) commercial forms diluted to drug concentrations of 2g.L-1 in deionised 
water; deionised water (d) and manitol solution at 10 g.L-1 in deionised water (e). Spectra are 
offset for clarity.  
Figure 2 presents mean Raman spectra collected from the commercial forms of the three 
chemotherapeutic drugs, TEVA® (spectrum a), MYLAN® (spectrum b) and CERUBIDINE® 
(spectrum c) diluted to concentrations of 2 g.L-1 in deionised water. As expected, due to their 
similar chromophores, spectral signatures display strong similarities, all major peaks being found 
in all 3 formulations. To further represent the vibrational modes observed, Table 1 provides a direct 
comparison of their positions with corresponding assignments. The differences observed are 
relatively minor, especially for TEVA® (spectrum a) vs MYLAN® (spectrum b), which show 
only a 2 cm-1 shift between 1089 cm-1 vs 1091 cm-1. With the exception of the band at 886 cm-1 
observed in the case of CERUBIDINE®, all other features appear consistent for the 3 molecules, 
as seen in Figure 2. Moreover, the recording of Raman spectra from liquid samples can lead to 
some underlying contribution from water. Although the Raman bands observed have strong 
intensities, the profile of the signal and the band around 1600-1650 cm-1 (Figure 2) suggest that 
H2O (spectrum d) also contributes to the spectra of the drug solutions. The features observed 
around 450 cm-1 and 1300 cm-1 in the water spectrum are respectively assigned to the quartz cuvette 
and the glass of the focusing lens of the macro adapter used. In comparison to the short side chains, 
the intensity of the peaks associated to the conjugated chromophores is dominant, due to their high 
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Raman activity. Consequently, no major spectral differences can be observed between the 3 
formulations. Moreover, in contrast, molecules such as NaOH and HCl do not have any significant 
contribution to the spectra. In the solution of 2 g.L-1 CERUBIDINE®, mannitol is found at 10 g.L-
1. Despite the relatively high concentration, the Raman spectrum collected from the mannitol 
aqueous solution does not exhibit strong features, and the only difference with the water spectrum 
is at 886 cm-1, where a weak peak arises from the broad background (spectrum 2e).   
 
Table 1: Bands assignments of main features observed in the finger print region of TEVA®, 
MYLAN® and CERUBIDINE® Raman spectra collected from 2 g.L-1 solutions in deionized water 
[33-37].  
TEVA® 
(cm-1) 
MYLAN® 
(cm-1) 
CERUBIDI
NE® (cm-1) 
Assignments 
355 350 351 - 
446 446 447 C-C-O vibrations , C=O in plane 
deformation   
- - 886 - 
1000 1000 998 C-C stretching of alicyclic ring  
1089 1091 1091 Ring breathing and aromatic C-H bending 
vibrations, methoxy C-O stretching and C-
C aliphatic chain vibrations 
1219 1219 1219 C-O-H vibrations and in plane bending of 
O-H  
1250 1250 1251 C-O vibrations  
1309 1309 1311 C-O-H vibrations   
1445 1445 1453 Aromatic ring stretching modes  
1582 1582 1586 Aromatic ring stretching   
1647 1647 1650 Hydrogen bonded stretching vibrations of 
C=O  
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3.2.2 Discriminant analysis using PCA-FDA  
Discriminant and quantitative analysis are two aspects of the data mining process not necessarily 
achieved through similar approaches, although they remain strongly connected. One could 
consider that any measurements of concentrations performed cannot be validated without 
identifying the molecule in solution being analysed. Therefore, it appears to be more relevant to 
first identify the drug and then aim for the quantification. While the quantitative analysis can 
establish a correlation between the intensity of the signal and the concentrations measured, when 
it comes to discriminating data sets based on the molecular information of the spectra, the overall 
intensity should be disregarded in favour of band positions, number and intensity ratios. 
Consequently, in the present study, it has been considered more relevant to subject the spectra to 
both baseline correction and vector normalisation prior to PCA-FDA. Thus, the concentration 
parameter has been removed from the analysis, focusing solely on the variations described above. 
Moreover, two methods for baseline correction have been evaluated, the Lieber correction [38] 
and EMSC [39].  
PCA is a well-established unsupervised approach for rapid evaluation of spectral variability in 
complex data sets. Intensively used for analysis of IR and Raman spectra collected from biological 
samples, it readily allows visualisation of possible discrimination of samples using scatter plots 
[40, 41]. Figure 3A displays the scatter plot obtained for Raman spectra collected from 2 g.L-1 
TEVA®, MYLAN® and CERUBIDINE® subjected to Lieber baseline correction followed by 
vector normalisation. Although spectral differences are not conspicuous after preprocessing, the 
scatter plot presents three well separated groups, corresponding to each formulation. It can be seen 
that, according to Principal Component 1 (PC1), spectra collected from CERUBIDINE® are well 
separated from the others (Figure 3A red cluster), while TEVA® and MYLAN® data are only 
discriminated according to Principal Component 2 (PC2) (Figure 3A blue and green clusters).  
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Figure 3: PCA of Raman data collected from TEVA® (blue), MYLAN® (green) and 
CERUBIDINE® (red) 2 g.L-1 solutions in deionised water. A and B: scatter plot of PC1 and PC2 
with corresponding loadings 1 and 2 obtained from data subjected to Lieber baseline correction 
and vector normalization; C and D: scatter plot of PC1 and PC2 with corresponding loadings 1 
and 2 obtained from data subjected to EMSC correction and vector normalization. Loading are 
offset for clarity.   
 
The loadings corresponding to each PC are displayed in Figure 3B, highlighting the spectral 
features leading to the distribution of the data points in the scatter plot. Dominant features in the 
loading of PC1 observed at 447 cm-1, 891 cm-1, 1096 cm-1, 1221 cm-1, 1263 cm-1 and 1301 cm-1, 
1411 cm-1, 1472 cm-1 and 1641 cm-1 correspond to dominant peaks previously identified in the 
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mean spectra (Table 1). Loading 2, only accounting for 4.4% of the explained variance 
discriminating TEVA® (blue) and MYLAN® (green), displays a lower number of strong features  
(357 cm-1, 475 cm-1, 1210 cm-1, 1306 cm-1, and 1448 cm-1). These 2 forms are really similar with 
only NaOH and HCl as excipients which have no contribution to the spectral signatures recorded. 
The features of the loading of PC2 are common to the Raman spectra of both compounds, as shown 
in Figure 2, but the differentiating features suggest that small shifts can result from the different 
stereo-chemistry of the molecules.      
Although PCA performed using a single concentration (i.e. 2 g.L-1) exhibits clear separation of the 
three clusters and thus possible identification of the different chemotherapeutic forms, it is also 
important to address the need to perform discriminant analysis as an overall classifier, including 
all concentrations. The spectra in Figure 2 illustrate how similar the Raman spectra of the three 
formulations are, and the PCA in Figure 3 indicates that any variations between them are minor 
differences in peaks positions and intensities. Applying PCA to the range of possible combinations 
of concentrations would require considerable effort, and thus other multivariate approaches such 
as PCA-FDA need to be implemented. All the different concentrations and drug types have been 
considered as distinct groups to classify (n = 24). The approach is supervised and implementation 
of a cross validation procedure is necessary to ensure the robustness of discrimination observed. 
Specifically, 1/3 of the data was used as a validation set and for each iteration of the 100-fold leave 
K-out cross validation, calibration and validation sets were constituted from the 2/3 of the 
remaining spectra. To better appreciate the specificity and sensitivity of the discrimination, at each 
iteration of the cross validation, results obtained with a model based on 4 principal components 
are reported in a confusion matrix (Table 3). This step of the analysis aims purely to discriminate 
the different anti-cancer drugs without any significance given to their concentrations. Therefore, 
successful classification was judged solely on the ability to identify the correct drug corresponding 
to the test spectra, irrespective of the concentration assignment. Although the overall specificity 
and sensitivity obtained are above 90%, the results are concentration and molecule dependent, and 
in some cases exhibit rather low values, as for example the TEVA® S7 (specificity = 85%), 
MYLAN® S1 (specificity = 75%) or CERUBIDINE®  S1 (sensitivity 50%) (Table 3).  
Although the results are encouraging, observation made in Figure 2 of minimal spectral differences 
between TEVA® and MYLAN® formulations, the specificity of the classification achieved is 
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somehow surprising. Raman spectroscopy is a technique particularly sensitive to changes of the 
light scattering when performing analysis on liquid samples. While the dynamic range of 
concentrations tested could lead to inconsistencies in the measurements, solutions of commercial 
formulations also contain excipients which possibly contribute to the spectra collected, not 
necessarily in terms of spectral features considering the concentrations, but rather affecting the 
baseline (or background) through scattering [42]. For this reason, more advanced baseline 
correction, taking into account the water spectrum has been performed by means of EMSC coupled 
to vector normalisation prior to PCA (Figure 3C and D). While the scatter plot from the PCA still 
displays clear separation between data groups according to formulation (Figure 3C), the 
corresponding loadings of PC1 and PC2 are strongly affected, and retain only residual features at 
895 cm-1, 
918 cm-1, 993 cm-1, 1096 cm-1, 1180 cm-1, 1265 cm-1, 1471 cm-1. Clearly, a standard baseline 
correction does not take into account the changes in band ratios induced by underlying background 
in the spectra possibly leading to misinterpretation of results. Following EMSC, both the residual 
water and background are removed and relative band intensities are more accurately corrected. 
Consequently, when performing the PCA-FDA, the outcome is also affected and the overall 
specificity and sensitivity are now found to respectively be between 64.4% - 72.5% and 53.3% - 
59.2% with the classification model constructed using 3 principal components (Table 4). A number 
of concentrations exhibit values below 50%, which indicates that a non-negligible number of mis-
classifications have occurred, thus raising some serious concerns about the choice of data 
preprocessing having high impact on the analysis outcome and consequently the robustness of 
Raman spectroscopy measurements for drug identification can be questioned. In some cases, such 
as TEVA® S3 and CERUBIDINE® S4, there is obviously a reduced reliability in the drug 
identification, which for high concentrations can generate higher risks of dose intoxication of 
patients. Moreover, at lower concentrations, the accuracy is also not suitable for accurate 
classification, suggesting the specificity of Raman is not sufficient. EMSC is an advanced 
correction method able to remove instrumental and/or experimental interferences. However, 
despite applying such correction, the outcome of the PCA-FDA remains quite disappointing, 
suggesting that the sensitivity and specificity observed are directly linked to the ability of the 
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technique to discriminate the 3 therapeutic solutions rather than the underlying source of 
variability.   
     
   Table 3: Specificity and sensitivity % of PCA_FDA for Raman data processed without EMSC.              
 
 
 
Table 4: Specificity and sensitivity % of PCA_FDA for Raman data with EMSC.    
 
 
3.2.3 Quantitative analysis using PLSR 
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Figure 4: Mean Raman spectra of the finger print regions collected from TEVA® following 
serial dilutions. Corresponding drug concentrations are 2g.L-1 (blue), 1.5g.L-1 (red), 1g.L-1 
(green), 0.5 g.L-1 (yellow), 0.25g.L-1(black), 0.125 g.L-1 (cyan), 0.0625 g.L-1 (magenta), 0.03125 
g.L-1 (grey), water (violet). Spectra are offset for clarity. 
 
While examination of spectra allows identification of the anti-cancer drug with a reasonably high 
degree of accuracy, the linear relationship existing between the intensity of the peaks and the 
concentrations prepared can be examined and used as a quantitative prediction model using PLSR. 
Due to the experimental macro set up used in this study, the reproducibility achieved during the 
measurements enables unambiguous monitoring of the decrease of the peak intensities according 
to the dilutions performed, as illustrated for the example of TEVA® in Figure 4. PLSR is a reliable 
method to evaluate the quantitative information contained in the data sets collected. However, in 
order to ensure maximum statistical relevancy, cross validation procedures are generally 
implemented [30], in order to demonstrate that the analysis is not biased, but also to test the 
robustness of the predictive model used. Considering the size of the number of spectra available 
for each concentration, a 100-fold leave K out cross validation with 2/3 of spectra used as 
calibration and the remaining 1/3 as validation has been preferred for this study. The calibration 
and validation are therefore completely independent and selected randomly at each iteration of the 
cross validation, enabling testing of numerous data combinations. The first graph generated during 
the analysis represents the Root Mean Square Error of Calibration (RMSEC) according to the 
number of dimensions used to regress the data (Figure 5A). As a supervised method, and aiming 
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to deliver the lowest RMSEC and thus the best precision, a gradual decrease towards 0 is expected 
as the number of dimensions employed in the model increases. Once the model has been 
established using the calibration set, it is then evaluated with the validation spectra. The Figure 5B 
exhibits first a steep decrease in the RMSECV (validation) before slightly increasing a stabilizing 
around 0.015 g.L-1. All dimensions calculated from the calibration set are not relevant to the 
quantification, and according to Figure 5B, above 3 dimensions over fitting of the data could 
actually affect the precision of the predictive model. Consequently, the regression plot has been 
implemented using three dimensions, and is presented in Figure 5C. The correlation between 
observed concentration (true concentrations) and predicted concentrations (experimental 
concentrations) delivers a linear trend characterised by R2 value of 0.9997 (Table 5). The error 
bars illustrate the standard deviation calculated from the 100 fold cross validation and further 
support the high reproducibility of the measurements. The overall RMSECV reached was found 
to be 0.0127 g.L-1 for TEVA® (Table 5). The numbers of dimensions used to construct the PLSR 
predictive models, respectively 3, 5 and 5 for TEVA®, MYLAN® and DNR, are also indicated in 
Table 5. Figure 5D shows the weighting vector corresponding to the PLSR analysis performed on 
TEVA® solutions. It represents the wavenumbers used to construct the predictive models, 
confirming the molecular specificity of the analysis has been preserved. The features with major 
contribution in the PLSR model can be found at 354 cm-1, 445 cm-1, 1000 cm-1, 1090 cm-1, 1219 
cm-1, 1249 cm-1, 1309 cm-1, 1453 cm-1, 1581 cm-1, 1647 cm-1 which are the major spectral features 
previously observed in Figure 3 and Table 1. Finally, a similar approach has been employed for 
MYLAN® and CERUBIDINE® formulations, yielding respective RMSECV of 0.0173 g.L-1 and 
0.0220g.L-1, as summarised in Table 5. Although inconsistent between patients and hospital, the 
lowest administered concentration for doxorubicin is roughly 0.15 g.L-1, and therefore the 
corresponding RMSECV found of 0.0127 g.L-1 suggest overall imprecision of about 8.5%. 
Similarly for MYLAN® and CERUBIDINE®, the RMSECV respectively account for 5.8% and 
2.35% compared to the lowest doses typically prescribed (0.3 g.L-1 and 1.2 g.L-1). The lower limit 
of detection (LOD) calculated from the PLSR analysis indicates that Raman spectroscopy can pick 
up concentrations as low as 0.0290 g.L-1, XXX g.L-1  and XXX g.L-1 for respectively TEVA®, 
MYLAN® and CERUBIDINE® which are all more than 10 times below the lowest dose 
administered to patients.          
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Figure 5: PLSR analysis performed on TEVA®. A:  Standard deviation error of calibration; B: 
Standard deviation error of validation; C: Regression fitting and D: Weighting vector. Error 
bars represent the standard deviation  
 
 
Table 5: PLSR results obtained from the 3 chemotherapeutic drug solutions tested 
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3.3. Discriminant and quantitative analysis using ATR-IR spectroscopy  
          3.3.1. ATR-IR characterisation of anthracycline formulations    
                  
  
Figure 6: Mean ATR-IR spectra recorded from TEVA® (A), MYLAN® (B), CERUBIDINE® (C) 
formulations and Mannitol (D). All spectra were recorded from solutions with  final 
concentration of anticancer drugs at 2g.L-1. Spectra are offset for clarity.  
 
Although recent work has supported the feasibility to perform IR quantitative analysis with ATR-
IR from liquid samples [32, 43], in the present study the anti-cancer drug concentrations involved 
are not sufficient to overcome the strong contribution of the water bands, which completely swamp 
the features of interest (data not shown). Consequently, air drying of samples following deposition 
onto the ATR crystal is required to collect exploitable data. Figure 6 displays the fingerprint region 
of mean spectra collected from the 3 different formulations. TEVA® and MYLAN® (Figure 6 A 
and B) deliver spectral signatures with high degree of similarity, but comparison of the peaks 
positions would suggest some variations in the range 700-1200 cm-1 can be observed (Table 6). 
Interestingly, the major difference compared to Raman spectroscopy is the weaker contribution of 
conjugated chromophores in the signatures collected. Consequently, other contributions from side 
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chains and excipients can be somehow enhanced and more easily detected. For instance, the 
CERUBIDINE® mean spectrum differs from the other two without any possible ambiguity. This 
can be explained by the presence of a high amount of mannitol in the formulation, obviously 
delivering strong features in the IR signature (Figure 6d). Summarised in Table 6, the most intense 
mannitol features at 1454 cm-1, 1085 cm-1, 1023 cm-1, 875 cm-1, 932 cm-1 and 890 cm-1 clearly 
dominate in the spectrum. However, a comparison between the IR spectrum collected from 
CERUBIDINE® (Figure 6c) and the pure spectrum of mannitol highlights that, despite the lower 
band intensities, specific contributions from daunorubicin can be identified at 1712 cm-1, 1617 cm-
1, 1582 cm-1, 1411 cm-1, 1202 cm-1, 1110 cm-1, 996 cm-1 and 984 cm-1.  
 
 
 
 
Table 6: Bands positions and assignments in ATR_IR spectra collected from TEVA®, MYLAN® 
and CERUBIDINE®. 
22 
 
 
 
 
3.3.2 Discriminant analysis using PCA-FDA  
Similar to Raman spectra, observations based on PCA enable a rapid visualisation of the spectral 
variability contained in the data set collected by ATR-IR. While Raman spectra from liquid 
samples can to some extent be affected by underlying background, the collection of infrared 
spectra using the ATR set up coupled to air dried drops drastically reduces any distortion of the 
baseline. Although recording of IR spectra from biological material such as cell or tissues in 
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transmission can lead to Mie or resonant Mie scattering effects [44], direct deposition of the 
solution on the ATR crystal minimises such phenomena. Consequently, only some offset in the 
data collected is observed according to the concentrations analysed, but such effects are easily 
compensated by implementation of a simple straight baseline subtraction such as the rubber band 
employed here. A rubber band correction with only 2 nodes at 1800 cm-1 and 600 cm-1 has the 
effect of bringing the spectral baseline down to 0 across the spectral range. Prior to performing the 
discriminant analysis, the concentration parameters have been removed using a vector 
normalisation to rescale all spectra.  
The PCA scatter plot displays strong separation of the three formulations according to PC1 and 
PC2, accounting respectively for 98.7% and 0.82% of the explained variance (Figure 7A). 
Similarly to Raman spectra, PC1 unambiguously differentiates TEVA® (Figure 7A blue) and 
MYLAN® (Figure 7A green) formulations from CERUBIDINE® (Figure 7A red). The 
corresponding loading suggests that PC1 is basically the spectral signature of mannitol, which is 
expected due to the strong features observed in the spectra of CERUBIDINE®. Notably, the bands 
at 1454 cm-1, 1085 cm-1, 1022 cm-1, 931 cm-1 and 717 cm-1 support this statement. PC2 
discriminates TEVA® (Figure 7A blue) from MYLAN® (Figure 7A green). The PCA tends to 
maximise the explained variance expressed by the first principal components. As a consequence 
of the strong contribution from the features assigned to mannitol, PC2 only accounts for 0.82%. 
This observation supports the presence of small variations in bands positions as previously 
witnessed and reported in Table 6. The features of loading 2 confirm that the discrimination is 
based on the differing spectroscopic profiles of the compounds but due to the scattering of 
CERUBIDINE® data points over the 2 other clusters in that dimension, it is unclear the 
discrimnation is genuine and peaks observed specific. Pairwise PCA is the most direct and 
unambiguous analysis to highlight the presence of discriminative wavenumbers between 2 datasets 
[28]. Figure 7C and 7D displays respectively the scatter plot and loading 1 for the PCA applied to 
TEVA® and MYLAN®. In absence of the CERUBIDINE® and associated strong mannitol bands 
the scatter plot naturally reorient itself to display a clear separation of TEVA® and MYLAN® 
along PC1 with an explained variance of 91.8%. The loading 1 corresponding to PC1 exhibits a 
quite large number of features but interestingly some of most intense located at 767 cm-1, 1014 
cm-1, 1060 cm-1, 1123 cm-1, 1212 cm-1, 1576 cm-1, 1615 cm-1 and 1719 cm-1 are either matching or 
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closely related to features found in TEVA® and MYLAN® as listed in Table 6. Despite, pairwise 
PCA is a relevant approach to investigate inter and intra data sets variability, it becomes relatively 
difficult to evaluate all combinations of data and estimate the discrimination rate when the number 
of samples is increasing. Therefore, more advanced methods such as PCA-FDA can be used.    
The outcome of the PCA-FDA obtained using 3 principal components is presented in Table 7, 
whereby, once again, the specificity and sensitivity has been calculated for each concentration 
analysed and for each drug. Using the ATR-IR spectra for discriminative analysis leads to high 
rates of correct classification with overall values equal or above 99.4%. A more detailed 
breakdown of the results shows that only the lowest concentrations tested, corresponding to 
0.03125 g.L-1, do not deliver 100% specificity and sensitivity for all 3 formulations. However, 
with 90% as the lowest outcome, the results remain quite satisfactory for accurate and reliable 
identification of formulations tested in respective formulations.                   
 
Figure 7: PCA of ATR_FTIR data collected from chemotherapeutic solutions at 2 g.L-1. A: 
Scatter plot of PC1 and PC 2 with TEVA® (blue), MYLAN® (green) and CERUBIDINE® (red). 
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B: Loading corresponding to PC1 (a) and PC2 (b). C: Pairwise PCA of ATR_FTIR from TEVA® 
(blue) and MYLAN® (green) and D: Loading corresponding to loading PC1     
 
 
            Table 7: Specificity and sensitivity % of PCA_FDA for ATR_FTIR.  
 
 
   
Considering the strong sugar features in the IR spectra collected from CERUBIDINE® it is 
obvious mannitol plays a major role in the discrimination. Despite, the main concern of the study 
is to investigate discrimination of solutions rather than solely the anticancer drugs, one could ask 
about the specificity of the analysis to actually differentiate the therapeutic solution containing 
CERUBIDINE® from pure solution of mannitol. This can be demonstrated thanks to a pair wise 
PCA performed from CERUBIDINE® solution at 0.03125 g.L-1, the lowest concentration 
presently tested, and mannitol solution at 0.15625g.L-1. The concentration of mannitol has been 
adjusted accordingly to the dilution factor of the stock solution of CERUBIDINE®. The scatter 
plot displayed in figure 8A exhibits a clear separation of the data along PC1 with 85.4% of the 
explained variance. Naturally, in a pair wise PCA the PC2 with 6.5% represents the intragroup 
variability. Loading 1 compared to the pure spectrum of mannitol highlights that a numerous 
spectral features are affected in presence of other molecules such as daunorubicin in the solutions. 
Therefore, the discrimination of CERUBIDINE® observed in the PCA-FDA is a combined 
contribution of both mannitol and other ingredients including the anticancer drug. Similar 
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observation are made with all concentrations included in this study (data not shown) which is 
perfectly understandable as the mannitol/daunorubicin ratio remains identical for all samples due 
to the same dilution factor applied during the preparation.       
 
Figure 8: PCA of ATR_FTIR data collected from CERUBIDINE® 0.03125 g.L-1 and Mannitol 
0.15625g.L-1. A: Scatter plot of PC1 and PC 2 with CERUBIDINE® (red) and Mannitol (blue). B: 
Reference spectrum of mannitol (a) and loading corresponding to PC1 (b). Spectra offset for 
clarity. 
 
 
 
3.3.3 Quantitative analysis using PLSR  
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Figure 9: Mean Raman spectra of fingerprint regions of TEVA® following serial dilutions. 
Spectra are organised as decreasing concentrations from the top to bottom, respectively 
corresponding to doxorubicin concentrations of 2g.L-1 (red), 1.5g.L-1 (green), 1g.L-1 (blue), 0.5 
g.L-1 (yellow), 0.25g.L-1 (black), 0.125 g.L-1 (magenta), 0.0625 g.L-1 (cyan), and 0.03125 g.L-1 
(grey). Spectra are offset for clarity 
 
Observation of the ATR-IR spectra collected from a set of TEVA® solutions highlights that the 
intensity of the absorbance tends to decrease according to concentration (Figure 9). It has been 
demonstrated that, while ATR-IR measurements can be used for quantitative analysis, the 
approach has a limited range of concentrations over which the Beer- Lambert law can be directly 
applied, whereby high concentration samples lead to a plateau effect with a loss of the linear 
relationship [43]. As the concentration increases, the thickness of the deposited residue film 
increases, to the extent that is comparable to the spatial extent of the evanescent field of the ATR. 
This can be accounted for by additional dilution of the higher concentrations. However, in the 
present study, it appears the dynamic range of concentrations is within the range of linearity of 
absorbance response. Similar to the case for Raman, the ATR-IR spectra have been subjected to 
PLSR analysis in order to evaluate how well correlated the spectral variations are with the 
concentration of the anticancer formulations. Figure 10 presents the different steps performed on 
the TEVA® form, as described previously in section 3.2.3. As observed with the Raman, the 
weighting vector extracted from the PLSR analysis is almost an identical copy of the mean spectra 
presented in Figure 10D, once more illustrating the molecular specificity of the analysis performed. 
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However, the behaviour of the RMSECV according the number of dimensions included in the 
analysis strongly differs compared to the Raman analysis. It tends to gradually decrease, with no 
clearly defined optimal number of dimensions which would ensure no overfitting of the model. 
Examination of the latent variables suggests that only the first 3 exhibit strong relevant features, 
while subsequent ones become increasingly dominated by noise and random bands. Therefore, 
considering the limited number of data in this investigation, it was deemed preferable to limit the 
number of dimensions to 3, in order not to deliver over optimistic results for the ATR-IR analysis. 
Ultimately, the outcome of the PLSR analysis delivers RMSECV higher than those observed with 
Raman spectroscopy, respectively 0.0558 g.L-1, 0.0573g.L-1 and 0.0759 g.L-1 for TEVA®, 
MYLAN® and CERUBIDINE® formulations (Table 8). Nevertheless, with R2 values all above 
0.99, the high degree of linearity in the PLSR model constructed with the IR data is demonstrated.  
However, although a multi-reflection crystal has been used, compared to the macro set up for the 
Raman experiments, the repeatability in the IR analysis remains lower, leading to loss of precision. 
In order to avoid over fitting of the results, the number of dimensions has been limited to 3 for the 
3 drugs. Ultimately the results demonstrate the limited quantitative capabilities of the approach 
when applied to anticancer formulations. For instance, the LOD calculated from the PLSR analysis 
are considerably higher than for Raman analysis. With LOD of  0.5802g.L-1 (TEVA®), XXX g.L-
1 (MYLAN®) and XXX g.L-1 (CERUBIDINE®) uncertainties in determination of the lowest 
concentrations question the reliability of ATR-IR for accurate quantification.    
 The Beer Lambert law is commonly employed to describe the linear relationship between 
concentration of an analyte in solution and its absorbance, facilitating quantitative analysis. When 
performing analysis of liquid samples, it is easy to comply with the basic requirements of uniform 
optical path length of the samples and sample homogeneity, to produce reliable results. Air drying 
the samples onto the ATR crystal inevitably raises questions about the uniformity and repeatability 
of the sample thickness, but also the risk of heterogeneous distribution and therefore sampling in 
multicomponent samples [45]. In recent years, concerns over the so-called “coffee ring effect” 
have been raised, in relation to ATR FTIR analysis of dried droplets. The effect refers to the 
tendency of molecular species to accumulate at the edge of the drop during the dry process [43-
44]. Depending on the sample concentration, the coffee ring effect can also lead to complete loss 
of the signal simply because the sample accumulates outside the area of measurement of the ATR 
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crystal [41]. Different types of crystals are commercially available, defined by the material of the 
crystal (for example diamond or germanium) but also the number of internal reflections. 
Importantly, the size of the crystal is also different and while a single reflection accessory delivers 
no signal from chemotherapeutic solutions analysed, due to this coffee ring effect (data not shown), 
the multi-reflection diamond crystal used in the present study offers a wider area for collection 
thus enabling the 2µL to be completely deposited within the recording area. However, although 
the multi-reflection accessory partially solves the limitation due to coffee ring effect, the 
heterogeneity of the samples after drying remains quite high, possibly also related to the precision 
of manual deposition of small volumes. 
 
Figure 10: PLSR analysis performed on TEVA®. A: Standard deviation error of calibration; B: 
Standard deviation error of validation; C: Regression fitting and D: Weighting vector. Error bars 
represent the standard deviation 
 
 
 
30 
 
Table 8: PLSR results obtained from the 3 chemotherapeutic solutions tested 
 
 
                    
 
Overall discussion 
 
Direct comparison between infrared and Raman spectroscopy has been conducted for the 
identification and quantification of 3 anthracyclines (TEVA®, MYLAN® and CERUBIDINE®) 
in solution, at clinically relevant concentrations (i.e. in the range of concentrations administered 
to patients). Data mining of spectral data sets with the help of multivariate analysis demonstrates 
that discrimination of drugs and predicting concentrations can be achieved with both techniques, 
although with different reliabilities. On the one hand, Raman spectroscopy displays the best 
precision for quantitative analysis, with RMSECV between 0.127-0.220 g.L-1 obtained from PLSR 
analysis, while on the other hand IR spectroscopy delivers higher sensitivity and specificity (above 
95%) for drug identification with PCA-FDA. Both techniques behave differently due to differences 
in the intrinsic nature of the signal collected. Raman spectroscopy is strongly dependent on 
polarisability of the molecules which, in the case of TEVA®, MYLAN® and CERUBIDINE®, 
results in spectra clearly dominated by contributions from the conjugated ring structures. In 
contrast, IR is sensitive to small variations in side-chains but also to additives. Commercial 
chemotherapeutic solutions are formulae or mixtures with different degrees of complexity, 
depending of the number of ingredients present. While usually the drug is the most concentrated 
chemical constituent of the solution, by many orders of magnitude, resulting in little or no 
contribution from the other constituents, in some cases the presence of a specific molecule in 
higher concentrations can change the balance and generate additional features in the spectral 
signatures. In CERUBIDINE®, for example, the presence of mannitol contributes significantly to 
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the profile of the infrared spectra, which are therefore representative of mixed contributions of the 
drug and the sugar used as additive. This does not represent a limitation of the technique, but rather 
a strength of ATR-IR compared to Raman, as manifest in the significantly improved discriminative 
power of the technique resulting in higher sensitivity in classification. Some ingredient or additive 
signatures, once combined with the spectral bands of the drug, can play the role of spectral markers 
for more reliable identification of the stock solution used to prepare the diluted solution. In the 
present study, TEVA®, MYLAN® and CERUBIDINE® are the one and only brand used for 
respectively doxorubicin, epirubicin and daunorubicin. Thus the spectral bands identified and used 
for discrimination will be reproducible and consistent over time. At present, quality control 
laboratories in hospitals typically employ flow injection analysis which is able to deliver accurate 
quantification for the majority of the 100+ solutions tested daily. The technique lacks the required 
specificity, however, when challenged with the discrimination of isomers such as TEVA®, 
MYLAN® and CERUBIDINE®, which display similar absorbance in the visible range, which can 
result in significant delays in administration of the solutions on a daily basis. As an augmentation 
to the current workflow, ATR-IR provides a potential solution for the rapid differentiation of the 
solutions. Performing the ATR analysis requires small volumes (few µL) compared to other 
current systems with injection of aliquots of at least 1.5 mL necessary. Considering the whole 
process of data analysis can be automated and completed in less than 1 minute, the overall time to 
get the result does not exceed 5 mins, which is comparable to systems already in use. Ultimately, 
ATR-IR spectroscopy is a cost effective technique with compact bench top apparatus that does not 
represent a huge capital investment and are increasingly user friendly, such that the data 
preprocessing and analysis routines can be easily incorporated into the instrument software and 
implemented in an automated protocol.  
 
4. Conclusion 
Both Raman and Infrared spectroscopy are valuable analytical tools with demonstrated potential 
for clinical applications. Although often proposed as complementary, instrumental set up would 
have a strong influence of their performance to a given application. The quantitative analysis of 
chemotherapeutic drugs can be achieved in solution with Raman spectroscopy or following air 
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drying with ATR-IR. In contrast, the discrimination of anthracyclines such as TEVA® 
(doxorubicin), MYLAN® (epirubicin) and CERUBIDINE® (daunorubicin) as part of quality 
control of therapeutic solutions suggests specificity of Raman analysis is more limited than that of 
IR. Although air drying is required for IR, analysis results are promising and enable both 
identification and quantification of all 3 molecules tested. With specificity and sensitivity above 
95%, ATR-IR spectrophotometry appears to be the most valuable approach to address current 
needs for discrimination of therapeutic solutions containing isomeric drugs and should be 
positioned as a highly relevant technique. Having an ATR just beside on the bench as a 
complementary tool to current techniques could provide an unambiguous identification in 5 mins. 
To summarise, ATR-IR spectrophotometry remains a cost effective, rapid and user friendly 
method which with optimization of methods would lead to fast implantation in the hospital routine.                     
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